Medindia LOGIN REGISTER
Medindia
Advertisement

SCYNEXIS to Participate in the Cantor Antibiotics Summit

Friday, January 12, 2018 Drug News
Advertisement
JERSEY CITY, N.J., Jan. 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled "Novel Ways to Treat and/or Address Infections" at the Cantor Antibiotics Summit at the Omni Berkshire Hotel, New York, on Wednesday, January 17, 2018 at 12:15 p.m. ET.
Advertisement

About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Advertisement

CONTACT:

Investor RelationsSusan KimArgot PartnersTel: [email protected]

Media RelationsCammy DuongMacDougall Biomedical CommunicationsTel: [email protected]  

Cision View original content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-the-cantor-antibiotics-summit-300581688.html

SOURCE SCYNEXIS, Inc.

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close